Performance of ProEx c and PreTect HPV-Proofer E6/E7 MRNA tests in comparison with the Hybrid Capture 2 HPV DNA test for triaging ASCUS and LSIL cytology

Diagnostic Cytopathology

Volumn 41, Issue 9, 2013, Pages 767-775

  Alaghehbandan, Reza ^a   Fontaine, Daniel ^b   Bentley, James ^c   Escott, Nicholas ^d   Ghatage, Prafull ^e   Lear, Adrian ^f   Coutlee, Francois ^g   Ratnam, Samuel ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d Regional Health Sciences Centre   (Canada)

^e TOM BAKER CANCER CENTRE   (Canada)

^f Dr H Bliss Murphy Cancer Centre   (Canada)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

ASCUS triage; CIN 2+; HC2; LSIL triage; PreTect HPV proofer; ProEx C

Indexed keywords

MESSENGER RNA; PROTEIN E6; PROTEIN E7; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SCREENING; COLPOSCOPY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; GENOTYPE; HC2; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PATIENT REFERRAL; PRIORITY JOURNAL; PROEX C; PROOFER; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ASCUS TRIAGE; CIN 2+; HC2; LSIL TRIAGE; PRETECT HPV-PROOFER; PROEX C;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; RNA, MESSENGER; ROC CURVE; SENSITIVITY AND SPECIFICITY; TRIAGE; UTERINE CERVICAL DYSPLASIA; YOUNG ADULT;

EID: 84883137119     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.22944     Document Type: Article

References (50)

1. Depuydt CE, Makar AP, Ruymbeke MJ, Benoy IH, Vereecken AJ, Bogers JJ,. BD-ProExC as adjunct molecular marker for improved detection of CIN2+ after HPV primary screening. Cancer Epidemiol Biomarkers Prev. 2011; 20: 628-637.
2. Thrall MJ, Smith DA, Mody DR,. Women ≥30 years of age with low grade squamous intraepithelial lesion (LSIL) have low positivity rates when cotested for high-risk human papillomavirus: Should we reconsider HPV triage for LSIL in older women? Diagn Cytopathol 2010; 38: 407-412.
3. Benevolo M, Vocaturo A, Caraceni D, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol 2011; 49: 2643-2650.
4. Schmidt D, Bergeron C, Denton KJ, et al. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: Results from the European equivocal or mildly abnormal papanicolaou cytology study. Cancer Cytopathol 2011; 119: 158-166.
5. Kulasingam SL, Kim JJ, Lawrence WF, et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst 2006; 18: 92-100.
6. Denton KJ, Bergeron C, Klement P, et al. The sensitivity and specificity of p16(INK4a) cytology vs. HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. Am J Clin Pathol 2010; 134: 12-21.
7. Petry KU, Schmidt D, Scherbring S, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol 2011; 121: 505-509.
8. Shroyer KR, Homer P, Heinz D, et al. Validation of a novel immunocytochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression in cervical cytology. Cancer 2006; 108: 324-330.
9. Pinto AP, Crum CP, Hirsch MS,. Molecular markers of early cervical neoplasia. Diagn Histopathol (Oxf) 2010; 16: 445-454.
10. Halloush RA, Akpolat I, Jim Zhai Q, et al. Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquid-based cervicovaginal material: A pilot study. Cancer 2008; 114: 474-480.
11. Siddiqui MT, Cohen C, Nassar A,. Detecting high-grade cervical disease on ASC-H cytology: Role of BD ProEx C and digene hybrid capture II HPV DNA testing. Am J Clin Pathol 2008; 130: 765-770.
12. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 7: 57-70.
13. Hanahan D, Weinberg RA,. Hallmarks of cancer: The next generation. Cell 2011; 4: 646-674.
14. Sotlar K, Stubner A, Diemer D, et al. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J Med Virol 2004; 74: 107-116.
15. Rösl F, Lengert M, Albrecht J, et al. Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids. J Virol 1994; 68: 2142-2150.
16. Keegan H, Mc Inerney J, Pilkington L, et al. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J Virol Methods 2009; 155: 61-66.
17. Cuschieri KS, Whitley MJ, Cubie HA,. Human papillomavirus type specific DNA and RNA persistence-Implications for cervical disease progression and monitoring. J Med Virol 2004; 73: 65-70.
18. Lie AK, Kristensen G,. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma. Expert Rev Mol Diagn 2008; 8: 405-415.
19. Lie AK, Risberg B, Borge B, et al. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 2005; 97: 908-915.
20. Molden T, Kraus I, Karlsen F, et al. Comparison of human papillomavirus messenger RNA and DNA detection: A cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 2005; 14: 367-372.
21. Kraus I, Molden T, Holm R, et al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol 2006; 44: 1310-1317.
22. Molden T, Kraus I, Skomedal H, et al. 2007. PreTect HPV-proofer: Real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J Virol Methods 142: 204-212.
23. Dockter J, Schroder A, Hill C, et al. Clinical performance of the APTIMA HPV assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 2009; 45: S55-S61.
24. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26: K1-16.
25. Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis. Br J Cancer 2003; 89: 101-105.
26. Cuzick, J, Arbyn M, Sankaranarayanan R, et al. 2008. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26: K29-K41.
27. Ratnam S, Coutlee F, Fontaine D, et al. Clinical performance of the PreTect HPV-proofer E6/E7 mRNA assay in comparison with that of the hybrid capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol 2010; 48: 2779-2785.
28. Sorbye SW, Fismen S, Gutteberg TJ, et al. HPV mRNA test in women with minor cervical lesions: Experience of the University Hospital of North Norway. J Virol Methods 2010; 169: 219-222.
29. Ratnam S, Coutlee F, Fontaine D, et al. Aptima HPV E6/E7 mRNA test is as sensitive as hybrid capture 2 assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol 2011; 49: 557-564.
30. Coutlée F, Ratnam S, Ramanakumar AV, et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol 2011; 83: 1034-1041.
31. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: Terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-2119.
32. Kelly D, Kincaid E, Fansler Z, et al. Detection of cervical high-grade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProEx™C). Cancer 2006; 108: 494-500.
33. Ratnam S, Franco EL, Ferenczy A,. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000; 9: 945-951.
34. Beccati MD, Buriani C, Pedriali M, et al. Quantitative detection of molecular markers ProEx C (minichromosome maintenance protein 2 and topoisomerase IIa) and MIB-1 in liquid-based cervical squamous cell cytology. Cancer 2008; 114: 196-203.
35. Siddiqui MT, Hornaman K, Cohen C, et al. ProEx C immunocytochemistry and high-risk human papillomavirus DNA testing in papanicolaou tests with atypical squamous cell (ASC-US) cytology: Correlation study with histologic biopsy. Arch Pathol Lab Med 2008; 132: 1648-1652.
36. Burger EA, KornâŠ̃r H, Klemp M, et al. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: A systematic review. Gynecol Oncol 2011; 120: 430-438.
37. Arbyn M, Buntinkx F, Van Ranst M, et al. Virologic versus cytologic triage of women with equivocal pap smears: A meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004; 96: 280-293.
38. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-520.
39. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-1101.
40. Molden T, Nygård JF, Kraus I, et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005; 114: 973-976.
41. Rebolj M, Bonde J, Njor SH, et al. Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: Systematic review. Br Med J (in press).
42. Szarewski A, Ambroisine L, Cadman L, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008; 17: 3033-3042.
43. Carreon JD, Sherman ME, Guillén D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: Results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007; 26: 441-446.
44. Badr RE, Walts AE, Chung F, et al. BD ProEx C: A sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol 2008; 32: 899-906.
45. Solomon D, Schiffman M, Tarone R,; ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial. J Natl Cancer Inst 2001; 93: 293-299.
46. Arbyn M, Martin-Hirsch P, Buntinx F, et al. Triage of women with equivocal or low-grade cervical cytology results: A meta-analysis of the HPV test positivity rate. J Cell Mol Med 2009; 13: 648-659.
47. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 2007; 121: 621-632.
48. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-1079.
49. Kraus I, Molden T, ErnâŠ̃ LE, et al. Human papillomavirus oncogenic expression in the dysplastic portio: An investigation of biopsies from 190 cervical cones. Br J Cancer 2004; 90: 1407-1413.
50. Beilby JO, Bourne R, Guillebaud J, et al. Paired cervical smears: A method of reducing the false-negative rate in population screening. Obstet Gynecol 1982; 60: 46-48.